Walleye Capital’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
Walleye Capital's ARCT Position: Q3 2026 in Review
Walleye Capital increased its Arcturus Therapeutics (ARCT) stake by 435% in Q3 2026, buying an estimated $879K and bringing the position to 103,415 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3142.
Walleye Capital first reported a position in ARCT in Q1 2021 and has held it in 7 quarters since. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.
- Walleye Capital held 103,415 shares of Arcturus Therapeutics worth $1.42M as of Q3 2026.
- Walleye Capital bought 84,092 Arcturus Therapeutics shares in Q3 2026, an estimated $879K.
- Arcturus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3142 holding.
- Walleye Capital first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 7 quarters since.
- 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.